This combination is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

This is a fixed-dose combination of a Rho kinase inhibitor and a Prostaglandin F2α analogue. Netarsudil is a Rho kinase inhibitor that works at the cellular level within the trabecular outflow pathway by relaxing actin-myosin. This causes relaxation of the trabecular meshwork and the inner wall of Schlemm's canal, helping to reduce episcleral venous pressure (EVP).

Latanoprost is a selective FP receptor agonist that lowers intraocular pressure by increasing the outflow of aqueous humor through the uveoscleral pathway.

The recommended dosage is one drop in the affected eye(s) once daily in the evening.

This eye drop is contraindicated in patients who are hypersensitive to any component of this preparation.

The most common ocular adverse reactions reported in controlled clinical studies with Netarsudil and Latanoprost were conjunctival hyperemia, pain at the instillation site, corneal verticillata, discomfort at the application site, foreign body sensation, and blurred vision in some patients.

There are no adequate and well-controlled studies of Netarsudil and Latanoprost combination in pregnant women to determine drug-related risk. There is also no available data regarding the presence of Netarsudil or Latanoprost in human milk, their effects on the breastfed infant, or their effects on milk production.

• For ophthalmic use only.
• To avoid contamination, do not touch the dropper tip to any surface.
• Use with caution in patients with active intraocular inflammation such as iritis or uveitis.
• It may cause gradual changes in pigmented tissues, eyelashes, and fine hair around the treated eye.
• Cystoid macular edema has been reported during treatment with Latanoprost. Reactivation of Herpes Simplex keratitis may also occur.
• This combination may be used with other topical ophthalmic products, but there should be at least a 5-minute interval between applications.

Pediatric Use: Safety and effectiveness in pediatric patients have not been established.

Use in elderly patients: No overall differences in safety and effectiveness have been observed between elderly and younger adult patients.

Drugs for miotics and glaucoma

Store at 2°-8°C in a dry place and protect from light until opened. After opening, the product may be kept at 2°-25°C for up to 6 weeks. Keep out of the reach of children.